AstraZeneca sold its 7.7 percent stake in Moderna for more than $1 billion: Report

Published On 2021-03-01 08:08 GMT   |   Update On 2021-03-01 08:08 GMT

New Delhi: AstraZeneca Plc has sold its 7.7% stake in Moderna Inc for more than $1 billion after the U.S. biotechnology company's shares soared on the back of its coronavirus vaccine breakthrough, The Times reported.

The report added that it was not clear over what period British-based AstraZeneca sold its holding in Moderna.
AstraZeneca and Moderna did not immediately respond to requests for comment.    
AstraZeneca is retaining partnership with Moderna on other disease treatments and could sell its AstraZeneca/Oxford University Covid-19 vaccine on a commercial basis in future if the virus becomes endemic, the report added.
Moderna, whose vaccine is cleared for emergency use against Covid-19 in the United States, said last week it was expecting sales of $18.4 billion from its coronavirus vaccine this year.


Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News